Displaying drugs 14776 - 14800 of 15494 in total
2-Nonyl-4-quinolinol 1-oxide
Experimental
(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL
Experimental
OSI-027
OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma.
Investigational
GSK-1292263
GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.
Investigational
Indole-3-carbinol
Indole 3 Carbinol is under investigation in clinical trial NCT00033345 (Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer).
Investigational
Iopydol
Experimental
S-3APG
S-3APG (S-3-[3-amino-phthalimido]-glutarimide) is a derivative of thalidomide with dual activity against B-cell neoplasias.
Investigational
Tridolgosir
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
Matched Description: … Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity. …
ATG003
ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
Investigational
Matched Description: … ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical …
Davanat
Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).
Investigational
Matched Description: … Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil …
Heparin, bovine
Heparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass).
Investigational
Matched Description: … Heparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated …
Proxalutamide
Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).
Investigational
Matched Description: … Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide …
Darigabat
Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder).
Investigational
Matched Description: … Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and …
AZD 3355
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Investigational
Matched Description: … It is developed by AstraZeneca and is currently in phase I/II trials. …
AZD-4017
AZD-4017 is under investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure).
Investigational
Matched Description: … investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and …
Giripladib
Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Investigational
Matched Description: … investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
DG041
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.
DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor ... first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and …
Tetraethylammonium
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … voltage- activated potassium channels, and nicotinic acetylcholine receptors. ... experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and ... still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and …
M0002
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Matched Description: … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce …
Displaying drugs 14776 - 14800 of 15494 in total